The Effect of Dexlansoprazole on Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis

• Published in: International journal of molecular sciences 2024-01, Vol.25 (2), p.1247
• Main Authors: Nunes, Gabriel Pereira, Silveira, Thayná Cerqueira, Marciano, João Vítor Silveira, Dos Reis-Prado, Alexandre Henrique, Ferrisse, Tulio Morandin, Dos Anjos, Evandro Barbosa, Fernandes, Maria Helena
• Format: Article
• Language: English
• Subjects: Bias; Clinical trials; dexlansoprazole; Dexlansoprazole - therapeutic use; Endoscopy; Esophagus; Gastroenterology; Gastroesophageal reflux; Gastroesophageal Reflux - drug therapy; Handbooks; Heartburn - chemically induced; Heartburn - drug therapy; Humans; Intervention; Medical research; Medicine, Experimental; meta-analysis; Patient compliance; Patients; PPI; Proton Pump Inhibitors - pharmacology; Proton Pump Inhibitors - therapeutic use; Risk assessment; Small intestine; Systematic review; Treatment Outcome
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25021247

This systematic review and meta-analysis evaluated the efficacy of dexlansoprazole (a proton pump inhibitor-PPI) in resolving heartburn, reflux, and other symptoms and complications resulting from gastroesophageal reflux disease (GERD). The study followed PRISMA 2020 and was registered in PROSPERO (CRD42020206513). The search strategy used MeSH and free terms appropriately adapted for each database. Only randomized clinical trials (RCTs) were included. The Cochrane tool (RoB 2.0) was used to assess the risk of bias, and the certainty of evidence was rated using GRADE. Ten RCTs were included. Dexlansoprazole outperformed the placebo and other PPIs in the resolution of heartburn and reflux symptoms in patients with GERD, with benefits during and after treatment, especially in those with moderate and severe symptoms. The meta-analyses indicated that dexlansoprazole at doses of 30 and 60 mg had more 24 h heartburn-free days and nights compared to the placebo medications; no difference was reported between dexlansoprazole at doses of 30 and 60 mg in heartburn-free nights. A low bias risk and a moderate certainty of evidence were observed. This review confirms the therapeutic effect of dexlansoprazole (placebo-controlled) and its improvements in GERD symptoms compared to another PPI. However, the interpretation of the results should be carried out cautiously due to the small number of included studies and other reported limitations.